Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'

Samankaltaisia teoksia

• Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
  Tekijä: Rowland, A, et al.
  Julkaistu: (2015)
• Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
  Tekijä: Hopkins, Ashley M, et al.
  Julkaistu: (2017)
• Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
  Tekijä: Hopkins, Ashley M, et al.
  Julkaistu: (2020)
• Nuances to precision dosing strategies of targeted cancer medicines
  Tekijä: Hopkins, Ashley M., et al.
  Julkaistu: (2020)
• Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
  Tekijä: Hopkins, Ashley M., et al.
  Julkaistu: (2021)